Cargando…

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer

INTRODUCTION: Therapeutically induced androgen deficiency (AD) is a standard treatment for patients with prostate cancer, but it is often associated with various adverse effects (AEs) that may lead to discontinuation. Some AEs may depend on the patient’s health condition, while others may be due to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokiwa, Suguru, Shimmura, Hiroaki, Nomura, Shuhei, Watanabe, Ryota, Kurita, Minoru, Yoshida, Naoto, Yamashita, Kaori, Nishikawa, Yoshitaka, Kouzmenko, Alexander, Kato, Shigeaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724412/ https://www.ncbi.nlm.nih.gov/pubmed/29264358 http://dx.doi.org/10.2147/RRU.S146180

Ejemplares similares

Painless vascular leiomyoma found after incision of the vaginal wall: A case report
por: Yamashita, Kaori, et al.
Publicado: (2017)

Profiling of Androgen-Dependent Enhancer RNAs Expression in Human Prostate Tumors: Search for Malignancy Transition Markers
por: Nishimura, Koichi, et al.
Publicado: (2021)

Whole body counter assessment of internal radiocontamination in patients with end-stage renal disease living in areas affected by the Fukushima Daiichi nuclear power plant disaster: a retrospective observational study
por: Shimmura, Hiroaki, et al.
Publicado: (2015)

Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)

Managing Type 2 Diabetes Mellitus through Periodical Hospital Visits in the Aftermath of the Great East Japan Earthquake Disaster: A Retrospective Case Series
por: Nishikawa, Yoshitaka, et al.
Publicado: (2015)

PPAR-γ Signaling Crosstalk in Mesenchymal Stem Cells
por: Takada, Ichiro, et al.
Publicado: (2010)

Degarelix and its therapeutic potential in the treatment of prostate cancer
por: Doehn, Christian, et al.
Publicado: (2009)

Minimal Internal Radiation Exposure in Residents Living South of the Fukushima Daiichi Nuclear Power Plant Disaster
por: Akiyama, Junichi, et al.
Publicado: (2015)

Individual external doses below the lowest reference level of 1 mSv per year five years after the 2011 Fukushima nuclear accident among all children in Soma City, Fukushima: A retrospective observational study
por: Tsubokura, Masaharu, et al.
Publicado: (2017)

Investigation of the GnRH antagonist degarelix isomerization in biological matrices
por: Ferrazzano, Lucia, et al.
Publicado: (2023)

The Function of the Vitamin D Receptor and a Possible Role of Enhancer RNA in Epigenomic Regulation of Target Genes: Implications for Bone Metabolism
por: Sawatsubashi, Shun, et al.
Publicado: (2019)

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
por: Rick, Ferenc G, et al.
Publicado: (2013)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Inhibitory effects of long-term repeated treatments of a sustainable GnRH antagonist, degarelix acetate, on caprine testicular functions
por: KAWATE, Noritoshi, et al.
Publicado: (2020)

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012)

Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
por: Ong, Shawn Y., et al.
Publicado: (2015)

Mistaken administration of a repeat loading dose of Degarelix leading to acute psychosis
por: Hamdoon, Musaab, et al.
Publicado: (2021)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats
por: Jayusman, Putri Ayu, et al.
Publicado: (2018)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
por: Madhu, Basetti, et al.
Publicado: (2016)

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
por: Sun, Yinghao, et al.
Publicado: (2020)

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
por: Roshani, Hossain, et al.
Publicado: (2021)

Effects of Docetaxel plus Degarelix on Quality of Life and Vascular Endothelial Growth Factor in Patients with Prostate Cancer
por: Li, Weiping, et al.
Publicado: (2022)

Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
por: Hosseini, Seyed Alireza, et al.
Publicado: (2016)

In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
por: Sakai, Monica, et al.
Publicado: (2015)

Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety
por: Merola, David, et al.
Publicado: (2022)

Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2
por: Tanaka, Kanta, et al.
Publicado: (2022)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Association of antithrombotic therapy with postoperative rebleeding in patients with cerebral amyloid angiopathy
por: Yanagawa, Taro, et al.
Publicado: (2023)

Thiourea fused γ-amino alcohol organocatalysts for asymmetric Mannich reaction of β-keto active methylene compounds with imines
por: Nomura, Miku, et al.
Publicado: (2023)

Comparative risk assessment of non-communicable diseases by evacuation scenario– a retrospective study in the 7 years following the Fukushima Daiichi nuclear power plant accident
por: Nomura, Shuhei, et al.
Publicado: (2021)

Marine Antithrombotics
por: Dwivedi, Rohini, et al.
Publicado: (2020)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
por: You, Dalsan, et al.
Publicado: (2015)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
por: Sciarra, Alessandro, et al.
Publicado: (2016)

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
por: Sciarra, Alessandro, et al.
Publicado: (2021)

Towards a Long-Term Strategy for Voluntary-Based Internal Radiation Contamination Monitoring: Representativeness of the Monitoring Results in Fukushima, Japan
por: Nomura, Shuhei, et al.
Publicado: (2017)

Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(−/−) mice
por: Knutsson, Anki, et al.
Publicado: (2016)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer: Erratum
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kdjn911gh5snki5vkm5ahmm4t6